Clinical Trial

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
Protocol Amendment History 4 changes
notable Primary completion pushed: 2026-07-01 -> 2026-10-01 2026-08-15
minor Completion pushed: 2026-07-01 -> 2026-10-01 2026-08-15
notable Primary completion pushed: 2026-04-01 -> 2026-07-01 2026-04-29
minor Completion pushed: 2026-04-01 -> 2026-07-01 2026-04-29
Trial Details
NCT Number NCT06504290
Lead Sponsor Vigonvita Life Sciences
Conditions Schizophrenia
Enrollment 40 participants
Start Date 2024-07-16
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14